Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (Nasdaq: VCYT) is a global cancer diagnostics and genomic testing company whose news flow centers on clinical evidence, test performance, and financial results. The company describes its mission as transforming cancer care by empowering clinicians with high-value insights at key decision points in diagnosis and treatment. Its Veracyte Diagnostics Platform underpins tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, along with research tools like Afirma GRID and Decipher GRID.
On this page, readers can follow Veracyte news related to quarterly and annual financial results, including revenue and testing volume updates the company announces in earnings press releases and accompanying conference calls. Veracyte’s communications also highlight non-GAAP measures such as adjusted EBITDA and adjusted EBITDA margin, along with explanations of how these metrics are used internally and how they differ from GAAP figures.
Another major category of news involves clinical and scientific developments. Veracyte regularly reports on studies and abstracts that use its Afirma GRID and Decipher GRID platforms to develop and evaluate molecular signatures in thyroid and prostate cancer. Examples include publications on Afirma GRID-derived signatures to differentiate thyroid cancer risk groups and prospective validation data for biomarkers such as the PAM50 molecular signature in recurrent prostate cancer.
Investors and clinicians can also find announcements about Veracyte’s participation in healthcare and investor conferences, where management presents updates on the company’s diagnostics portfolio, research programs, and financial outlook. For ongoing insight into how Veracyte’s genomic tests and research tools are being used in practice and studied in trials, this news feed aggregates the company’s press releases and related updates in one place.
Veracyte, Inc. (Nasdaq: VCYT) announced preliminary results for Q4 and FY 2020, projecting total revenue between $34.0 million and $35.0 million for the fourth quarter, and between $117.0 million and $118.0 million for the full year, reflecting a 16% increase in Q4 revenue year-over-year. Testing volume also rose by 14% compared to 2019. The company expects cash equivalents of $345.0 million to $350.0 million as of year-end. CEO Bonnie Anderson highlighted the team's performance and robust pipeline as key to future growth.
Veracyte, Inc (Nasdaq: VCYT) announced that its CEO Bonnie Anderson will present at the 23rd Annual Needham Virtual Growth Conference on January 13, 2021, at 4:15 p.m. ET. A live audio webcast of the presentation will be accessible via the company’s website, with a replay available for 90 days thereafter. Veracyte is a global genomic diagnostics company focused on improving patient care through advanced genomic testing for diseases such as cancer.
Bayer and Veracyte are collaborating to enhance the Precision Oncology Patient Identification Program for thyroid cancer. This initiative will utilize Veracyte's Afirma Xpression Atlas to detect genomic drivers, including NTRK gene fusions, in patients with advanced or radioactive iodine refractory (RAIR) thyroid cancer. The program will provide Afirma XA testing at no cost for eligible patients, supporting informed treatment decisions. Launched in Q1 next year, it aims to help patients with actionable alterations access targeted therapies, impacting approximately 53,000 annual thyroid cancer diagnoses in the U.S.
Summary not available.
Veracyte, Inc. (Nasdaq: VCYT) has revealed preliminary performance data for its noninvasive nasal swab test aimed at early lung cancer detection and the Percepta Genomic Atlas for treatment decisions. Scheduled for launch in late 2021, these tests leverage genomic profiling to cater to patient needs. Initial data indicated that 44-60% of malignant nodules were correctly classified as high-risk, with high specificity (90-91%). Additionally, the Percepta Genomic Atlas demonstrated over 95% accuracy in detecting gene variants in lung cancer. Veracyte continues its commitment to enhancing lung cancer diagnostics.
Veracyte, a global genomic diagnostics company, will host a Virtual Lung Cancer R&D Day on December 16, 2020, from 10:00 a.m. to 12:00 p.m. EST. The event will showcase senior management discussing the company’s vision for lung cancer patient care and updates on its product pipeline including the Nasal Swab Test and Percepta Atlas, set to launch in the second half of 2021. Investors can register for the event here.
Veracyte, a global genomic diagnostics company, announced that CEO Bonnie Anderson will participate in a fireside chat and one-on-one meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The pre-recorded chat will be available on the conference website, with a replay accessible on Veracyte's site for 90 days post-event. Veracyte provides genomic tests for various cancers, improving patient care by enabling quicker diagnoses and treatment decisions. For more information, visit www.veracyte.com.
Veracyte (Nasdaq: VCYT) has announced a new general manager-based structure to fuel its genomic tests and global expansion. Effective January 1, 2021, John Hanna, the current chief commercial officer, will lead the endocrinology, breast cancer, and lymphoma divisions, while Morten Frost will oversee the pulmonology sector. Notably, Hanna's management has doubled genomic test volume and revenue since 2017. The company anticipates launching four new products next year and aims to strategically manage its offerings to support long-term growth.
Veracyte (Nasdaq: VCYT) announces a new management structure to enhance its genomic testing portfolio and global expansion. John Hanna transitions to General Manager of endocrinology, breast cancer, and lymphoma, while Morten Frost joins as GM of pulmonology, effective January 1, 2021. Hanna will oversee the Afirma and Prosigna businesses, contributing around 90% of current revenue. Frost brings extensive experience to lead lung cancer strategies, targeting a $40 billion market. This restructuring aims to optimize growth and enhance strategic execution across product lines.
Veracyte, Inc. (Nasdaq: VCYT) announced that the Federal Joint Committee (G-BA) has approved reimbursement for its Prosigna® Breast Cancer Gene Signature Assay in Germany. This decision allows access for HR+/HER2- early-stage breast cancer patients. The Prosigna Assay employs advanced genomic technology to assess 50 genes, offering a prognostic score for cancer recurrence over 10 years.
The test is endorsed by major medical guidelines and aims to improve treatment decisions, benefiting approximately 70,000 women diagnosed with early breast cancer annually in Germany.
FAQ
What is the current stock price of Veracyte (VCYT)?
What is the market cap of Veracyte (VCYT)?
